| Title |
Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy
|
|---|---|
| Published in |
Journal of Cancer Research and Clinical Oncology, September 2013
|
| DOI | 10.1007/s00432-013-1510-5 |
| Pubmed ID | |
| Authors |
George Dranitsaris, Susanne Schmitz, Reuben J. Broom |
| Abstract |
Patients with metastatic renal cell carcinoma (mRCC) and a good performance status typically receive an anti-vascular endothelial growth factor receptor (VEGFR) TKI (sunitinib or pazopanib) as initial therapy. Upon disease progression or intolerance, there are four orally administered agents approved in the second-line setting (including cytokine-refractory). However, head-to-head comparative trial data are limited. In this study, an indirect statistical comparison of safety and efficacy was undertaken between axitinib, sorafenib, pazopanib and everolimus in second-line therapy mRCC. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 3 | 5% |
| Switzerland | 1 | 2% |
| Brazil | 1 | 2% |
| United Kingdom | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 56 | 89% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 27% |
| Student > Master | 10 | 16% |
| Other | 7 | 11% |
| Student > Ph. D. Student | 6 | 10% |
| Student > Bachelor | 5 | 8% |
| Other | 11 | 17% |
| Unknown | 7 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 51% |
| Agricultural and Biological Sciences | 5 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Nursing and Health Professions | 3 | 5% |
| Mathematics | 2 | 3% |
| Other | 7 | 11% |
| Unknown | 10 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2023.
All research outputs
#4,415,538
of 23,815,455 outputs
Outputs from Journal of Cancer Research and Clinical Oncology
#209
of 2,632 outputs
Outputs of similar age
#37,763
of 199,390 outputs
Outputs of similar age from Journal of Cancer Research and Clinical Oncology
#2
of 16 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,632 research outputs from this source. They receive a mean Attention Score of 3.6. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 199,390 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.